Personalized cancer vaccine trial halted early – what we know
Disease control
Terminated
This phase 2 trial tested a personalized cancer vaccine called TLPO in 63 people with various solid tumors. The vaccine was made from a patient's own tumor material to train their immune system to fight the cancer. The study aimed to see if the vaccine could delay disease progres…
Phase: PHASE2 • Sponsor: Elios Therapeutics, LLC • Aim: Disease control
Last updated Jun 26, 2026 16:56 UTC